# Philippe Armand

Source: https://onco.cc/people/philippe-armand/  
OnCo record `philippe-armand` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Boston lymphoma doctor who led KEYNOTE-170, the trial that showed pembrolizumab can control relapsed primary mediastinal B-cell lymphoma, and who helped bring PD-1 blockade to Hodgkin lymphoma.

## Summary

Philippe Armand is a lymphoma specialist at Dana-Farber Cancer Institute. He was first author of the 2019 Journal of Clinical Oncology report of KEYNOTE-170, in which pembrolizumab produced durable responses in relapsed or refractory primary mediastinal large B-cell lymphoma, supporting its approval in that setting, and was a lead investigator of the trials of nivolumab and pembrolizumab in relapsed classical Hodgkin lymphoma.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: lymphoma; immunotherapy; trialist
- Role: Lymphoma specialist, Dana-Farber Cancer Institute
- Specialisms: Hodgkin lymphoma; Primary mediastinal B-cell lymphoma; Checkpoint inhibitors in lymphoma

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Primary mediastinal (thymic) large B-cell lymphoma](https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/)
- institutions: [Dana-Farber Brigham Cancer Center](https://onco.cc/institutions/dana-farber/)
- key papers: [KEYNOTE-170: pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma](https://onco.cc/key-papers/paper-keynote-170-pembrolizumab-pmbcl-armand-jco-2019/)

---
JSON: https://onco.cc/api/v1/entities/philippe-armand.json